Glenmark Pharmaceuticals announced the sale of a 75% stake in its subsidiary company Glenmark Life Sciences to Nirma for $615 per share, for a total consideration of $5.651.75. With the equity reduction, the Mumbai-based drugmaker would retain...
In 2022, the worldwide antifibrinolytic medicines market is expected to be worth US$ 16.2 billion. In the future, it is predicted to rise to US$ 21.2 billion by 2028, with a compound annual growth rate (CAGR) of 4.5% from 2023 to...
Kezar Life Sciences, Inc, a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today announced that it entered into a collaboration and license agreement with...
Venus Remedies, based in Chandigarh, announced that it has received marketing authorization from Serbia for two oncology medications, gemcitabine and docetaxel. As a result of this, the business has received 511 marketing approvals for its...
The worldwide antifungal medications market was worth USD 13.81 billion in 2021 and is predicted to grow at a 3.6% CAGR over the forecast period. Increasing high-value investments in the healthcare sector, as well as R&D endeavors by big...
Derren Healthcare Private Limited (DHPL) and Genpharmasec Limited (SSSA) have signed a share purchase and share subscription cum shareholders' agreement (SSSA). Following that, Genpharmasec will gradually acquire a 70% share in DHPL over the...
Indian-origin computational Neuroscientist Dr Srikanth Ramaswamy has been announced as one of six new Fellows for the 2023 Lister prize for his early-career success that indicated an exceptional potential for future biomedical research. His work...
EffRx Pharmaceuticals SA, a commercial-stage pharmaceutical company focused on the development and commercialization of medications for musculoskeletal and rare diseases, announced that it has signed an exclusive licensing and distribution...
CureVac, in collaboration with GSK, recently announced the entry of its modified mRNA seasonal influenza vaccine candidate with multiple antigens into Phase II clinical trials. The preliminary results of Phase I trials demonstrated favorable...
BioNTech of Germany has announced a collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to further the development of its mpox vaccine. CEPI will provide funding of up to $90 million to support the development of vaccine...
, CDSCO.jpg)
